Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Lymphoma Gene Therapy
New lymphoma gene therapy research has been reported by scientists at University of Pennsylvania
September 17th, 2008
"Cell-based vaccination strategies to induce functional tumor-specific T cells in cancer patients have focused on using autologous dendritic cells. An alternative approach is to use RNA-loaded CD40 activated B cells (CD40-B) that are highly efficient antigen-presenting cells capable of priming naive T cells, boosting memory T-cell responses and breaking tolerance to tumor antigens," scientists writing in the journal Gene Therapy report. "The use of tumor RNA as the antigenic payload allows for gene transfer without viruses or vectors and permits major histocompatibility complex (MHC)independent, multiple-antigen targeting. Here, we use CD40L-transfected K562...
Source: Vaccine Weekly (2008-09-17)
|
